Sifan Chen

Dr. Sifan Chen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
XHXi He
Xi He
CLChenshu Liu
Chenshu Liu
JPJiangyun Peng
Jiangyun Peng
ZLZilun Li
Zilun Li
FLFang Li
Fang Li
CLChun-Liang Lei
Chun-Liang Lei
Abnormal glucose and lipid metabolism in COVID-19 patients were recently reported with unclear mechanism. In this study, we retrospectively investigated a cohort of COVID-19 patients without pre-existing metabolic-related diseases, and found new-onset insulin resistance, hyperglycemia, and decreased HDL-C in these patients. Mechanistically, SARS-CoV-2 infection increased the expression of RE1-silencing transcription factor (REST), which modulated the expression of secreted metabolic factors including myeloperoxidase, apelin, and myostatin at the transcriptional level, resulting in the perturbation of glucose and lipid metabolism. Furthermore, several lipids, including (±)5-HETE, (±)12-HETE, propionic acid, and isobutyric acid were identified as the potential biomarkers of COVID-19-induced metabolic dysregulation, especially in insulin resistance. Taken together, our study revealed insulin resistance as the direct cause of hyperglycemia upon COVID-19, and further illustrated the underlying mechanisms, providing potential therapeutic targets for COVID-19-induced metabolic complications.

11 February 2022 in Cell Metabolism
Verified
Journal Article
Closed access
ZLZilun Li
Zilun Li
MPMeixiu Peng
Meixiu Peng
PCPin Chen
Pin Chen
CLChenshu Liu
Chenshu Liu
AHAo Hu
Ao Hu
SCSifan Chen
Sifan Chen

31 January 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ZLZilun Li
Zilun Li
ZZZili Zhang
Zili Zhang
LKLiangru Ke
Liangru Ke
YSYanshuang Sun
Yanshuang Sun
WLWenxue Li
Wenxue Li
SCSifan Chen
Sifan Chen
Obesity has become an epidemic concern in modern society. The chronic obesity is associated with metabolic disorders, such as hyperglycemia, hyperlipidemia, fatty liver, and cadiovascular disease, which cause high risk for mortality. The novel potential strategy to overcome obesity is to “burn out” the extra fat via “browning” of the white adipose tissues. The phytochemical resveratrol (Res) has attracted substantial attention due to its powerful amelioratory effects in metabolic diseases. However, how Res regulates the browning of adipose tissues remains largely elusive. Our data show that the NAD + ‐dependent deacetylase silent information regulator 1 (Sirt1) mediates Res‐induced browning and fat reduction of adipocytes, as well as other Res‐improved metabolic phenotypes including hyperglycemina and hyperlipidemia in mice. Interestingly, we found that the major metabolites of Res in vivo (Res‐3‐O‐glucuronide, Res‐4′‐O‐glucuronide, and Res‐3‐O‐sulfate) were much less potent in promoting browning gene expressions and reducing fat content in comparison to Res itself in mouse and human adipocytes in vitro, suggesting the importance and necessarity to enhance the bioavailability of Res in vivo in consideration of therapeutic application. Taken together, our findings clarify the beneficial effects of Res on excess fat utilization via promotion of browning in a Sirt1‐dependent manner, suggesting the potential therapeutic application of Res in the treatment of obesity and related metabolic disorders.

23 February 2024 in Cell Metabolism
Verified
Journal Article
Closed access
KHKan Huang
Kan Huang
ZLZilun Li
Zilun Li
XHXi He
Xi He
JDJun Dai
Jun Dai
BHBingding Huang
Bingding Huang
SCSifan Chen
Sifan Chen

7 August 2025 in Nature Communications
Verified
Journal Article
Open access
ZZZhongyu Zhang
Zhongyu Zhang
ZZZhengde Zhao
Zhengde Zhao
XHXiuyi Huang
Xiuyi Huang
LZLifang Zhou
Lifang Zhou
XJXin Jiang
Xin Jiang
SCSifan Chen
Sifan Chen
Diabetic foot ulcers are severe diabetic complications, and promoting impaired angiogenesis is essential for wound healing. Pro-angiogenic galectin-3 is elevated in diabetic serum and promotes systemic insulin resistance that may impair wound healing. However, the exact role of galectin-3 in the regulation of diabetic wound healing remains unclear. Here, we demonstrate that galectin-3 promotes skin wound healing and angiogenesis via binding to its receptor integrin α5β1, and enhances downstream focal adhesion kinase phosphorylation by forming a liquid-liquid phase separation with integrin α5β1. Under diabetic conditions, aberrant accumulated advanced glycation end-products bind to galectin-3, blocking its interaction with integrin α5β1 and impairing angiogenesis. Topical treatment of recombinant galectin-3 in hydrogels promotes diabetic wound healing in rodents without causing systemic insulin resistance and synergizes with insulin. This study clarifies the binding of galectin-3 to integrin α5β1, instead of advanced glycation end-products, forming phase separation to promote angiogenesis and diabetic wound healing, laying the foundation for local galectin-3 therapy to treat diabetic foot ulcers.

3 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
DFDongxiao Fan
Dongxiao Fan
CLChenshu Liu
Chenshu Liu
ZZZhongyu Zhang
Zhongyu Zhang
KHKan Huang
Kan Huang
WTwang tengyao
wang tengyao
ZLZilun Li
Zilun Li
Vascular metabolic dysfunction presents in various diseases, such as atherosclerosis, hypertension, and diabetes mellitus. Due to the high prevalence of these diseases, it is important to explore treatment strategies to protect vascular function. Resveratrol (RSV), a natural polyphenolic phytochemical, is regarded as an agent to regulate metabolic pathways. Many studies have proven that RSV has beneficial effects on improving metabolism in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), which provide new directions to treat vascular metabolic diseases. Herein, we overviewed that RSV could regulate cell metabolism activity by inhibiting glucose uptake, suppressing glycolysis, preventing cells from fatty acid-related damages, reducing lipogenesis, increasing fatty acid oxidation, enhancing lipolysis, elevating uptake and synthesis of glutamine, and increasing NO release. Furthermore, in clinical trials, although the results from different studies remain controversial, we proposed that RSV had better therapeutic effects at high concentrations and for patients with metabolic disorders.